Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Novus Medical Detox Center Applauds CDC’s New Opioid Prescribing Guidelines but Calls for Additional Measures
  • USA - English


News provided by

JoTo PR

May 09, 2016, 08:00 ET

Share this article

Share toX

Share this article

Share toX

Bryn Wesch, CFO of Novus Medical Detox Center, calls for stronger regulations and appropriate treatment for drug overdose patients.
Bryn Wesch, CFO of Novus Medical Detox Center, calls for stronger regulations and appropriate treatment for drug overdose patients.
Youtube
Youtube

Clearly, there are flaws in the system if a patient who overdosed on opioids continues to be prescribed opioid painkillers.

Post this

NEW PORT RICHEY, Fla. (PRWEB) May 09, 2016 -- A recent study found that 91% of chronic-pain patients who survived an opioid overdose were dispensed prescription opioids again in less than year (1)—an alarming statistic considering that the death rate from prescription opioid overdoses nearly doubled from 2013 to 2014 (2). To reduce the risks associated with prescription opioid therapy, the Centers for Disease Control and Prevention (CDC) issued a new guideline for prescribing opioids for chronic pain (3). Novus Medical Detox Center, a leading Florida-based drug treatment facility, applauds the new CDC guideline as an important development but maintains that additional regulatory measures should be undertaken to prevent opioid overdoses, misuse and abuse, and to ensure patients with opioid use disorders receive proper treatment.

Key findings from the opioid prescribing study revealed that 7% of patients experienced another opioid overdose in less than a year; at two years, the incidence of repeat overdoses rose to 17% of patients receiving high dosages, 15% receiving medium dosages and 9% receiving low dosages. The study’s authors noted that existing guidelines clearly stated “misuse of opioids and adverse effects are compelling reasons to discontinue opioids.” Yet 70% of patients received their pre- and post-overdose prescriptions from the same doctor, and 41% of patients who overdosed had a documented substance use disorder (1).

Experts believe the study findings suggest several possibilities: prescribing doctors may have been unaware an overdose occurred, they may have had insufficient training in addressing chronic pain or addiction, they may have been reluctant to decrease the dosage patients believed they needed to function, and/or they may have feared that discontinuing opioid therapy would lead patients to turn to illicit opioids, such as heroin, for relief (4).

“Clearly, there are flaws in the system if a patient who overdosed on opioids continues to be prescribed opioid painkillers,” asserted Bryn Wesch, CFO of Novus Medical Detox Center. “While the new CDC prescribing guidelines aim to address some of these shortcomings, recommendations alone are not enough to solve the opioid epidemic. Stronger regulations and enforcement are essential to ensure patient safety and appropriate treatment for those with opioid use disorders.”

The new CDC guideline emphasizes that opioids should not be first-line or routine therapy for chronic pain and that nonopioid therapy is preferred. Clinicians are advised to monitor patients’ use of controlled substances via their state’s prescription drug monitoring program (PDMP) and through urine drug testing (3). While the guideline specifies what physicians “should” do, compliance is not legally mandated at a national level.

Wesch calls for regulations and systems that would alert doctors to previous overdoses and potential signs of substance abuse, and she advocates for mandatory training on chronic pain and substance use disorders. “If a patient still requests opioids after a previous overdose or if a doctor suspects the patient may resort to illicit drugs, I feel it is irresponsible to continue prescribing opioids,” said Wesch. “Physicians have a duty to ensure their patients receive appropriate care. In the case of overdose survivors, I believe that means pursuing alternatives to opioid therapy and referring individuals with substance use disorders to a qualified drug treatment program.”

Novus has helped many patients successfully manage opioid withdrawal with minimal pain and discomfort. The Florida detox facility provides medically supervised and individually customized treatment plans based on proven medical protocols, including 24-hour access to nursing care and withdrawal specialists. Novus is renowned for its expertise in treating high-dose methadone cases, and is equally proficient in detoxing other high-dose opioid cases just as safely, comfortably and effectively.

For more information on Novus Medical Detox Center and its prescription opioid detox programs, visit http://www.novusdetox.com.

About Novus Medical Detox Center:
Novus Medical Detox is a Joint Commission Accredited inpatient medical detox facility. Novus offers safe, effective alcohol and drug treatment programs in a tranquil, spa-like setting. Bordering a protected conservation area, Novus lies on 3.25 acres and provides a perfect setting for quiet walks. The facility is located in New Port Richey, Florida, and is licensed by the Florida Department of Children and Families. Novus is known for minimizing the discomfort of withdrawal from prescription medication, drugs and alcohol by creating a customized detox program for each patient. Incorporating medication, natural supplements and fluid replenishment, Novus tailors the detox process for each patient. There is 24/7 medical supervision, including round-the-clock nursing care and access to a withdrawal specialist. Novus’ expansion is tied to their contribution to their industry and their local community, ranking in the Florida Business Journal’s top 500, the Tampa Bay Business Journal’s Fast 50 and Inc. Magazine’s 500/5000 list of fastest-growing companies in America for the past three years. Novus has become a regular source to the media, including The Wall Street Journal and USA Today, as true advocates for standardization of care in detox to help more people get their lives back. For more information, visit http://www.novusdetox.com.

1. Larochelle, Marc R.; Jane M. Liebschutz; et al. “Opioid Prescribing After Nonfatal Overdose and Association With Repeated Overdose: A Cohort Study”; Annals of Internal Medicine; January 5, 2016. annals.org/article.aspx?articleid=2479117

2. Rudd, Rose A.; Noah Aleshire; et al. “Increases in Drug and Opioid Overdose Deaths — United States, 2000–2014”; Morbidity and Mortality Weekly Report; January 1, 2016. cdc.gov/mmwr/preview/mmwrhtml/mm6450a3.htm

3. Dowell, Deborah; Tamara M. Haegerich; and Roger Chou. “CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016”; Morbidity and Mortality Weekly Report; March 18, 2016. cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm

4. Gregg, Jessica. “Follow-up to Nonfatal Opioid Overdoses: More of the Same or an Opportunity for Change?”; Annals of Internal Medicine; January 5, 2016. annals.org/article.aspx?articleid=2479118

Karla Jo Helms, JoTo PR, +1 (888) 202-4614 Ext: 802, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.